GE HealthCare (Nasdaq: GEHC) aims to bolster its radiopharmaceutical supply chain with a $945 million cash deal to buy Sofie Biosciences and its U.S. network of manufacturing sites. The goal is to obtain last-mile logistics for radioactive imaging agents that have a short half-life and need to be produced as close to patients as possible.…

ISO 9001, ISO 14001 and ISO 45001 are all being revised, which leaves quality (QMS), environmental (EMS) and occupational health and safety (OH&S) managers, along with top management, with required work ahead to meet the new requirements. Because the revisions put more weight on climate change, resilience, ethics and people-related issues, they are more than…

Siemens Healthineers has teamed up with the recently rebranded drugmaker Novo on a project to advance its blood test for hidden liver disease, in a bid to deliver earlier diagnoses and access to treatment. Aimed at the category of metabolic dysfunction-associated steatotic liver disease, or MASLD —  and its progressive stage, metabolic dysfunction-associated steatohepatitis, commonly…

Artis BioSolutions announced the launch of its Genetics Medicines Center of Excellence in Bilbao, Spain, where it already has a facility specializing in synthetic DNA manufacturing. The company, which also has facilities in Boston and San Diego, supports genetic medicine developers with manufacturing processes. It was cofounded by Harvard University, MIT and Boston research hospitals as Landmark Bio.…

RayzeBio, a subsidiary of Bristol Myers Squibb, announced plans to construct a new $173 million facility in Whitestown, Indiana. The 225,000-square-foot facility will be located at the Anson Industrial Park in Boone County and will manufacture radiopharmaceutical therapies (RPTs). Construction is expected to begin this year. The company currently has a 77,000-square-foot RPT supply and manufacturing facility…

Bristol Myers Squibb (NYSE: BMY) announced it has selected Houston as the site for a new 600,000-square-foot multi-modal manufacturing campus, representing an approximately $2.3 billion investment. The campus, at Generation Park in Houston, will create nearly 500 skilled jobs, the company said.  The campus’ multi-modal capabilities will allow BMS to manufacture multiple types of medicines – such as…

Pharmaceutical manufacturing depends on repeatable inspection. A tablet with a crack, chip, stain, discoloration or other visible anomaly can signal a problem that deserves attention before product moves further downstream. Human inspection remains valuable, but it is inherently variable and difficult to scale consistently across long runs, multiple products and changing operators. Computer vision offers…

Codis announced today that it completed its previously announced acquisition of a UK-based manufacturing facility from Catalent. The Haverhill, England-based company agreed to acquire the oral solid dose (OSD) development and manufacturing plant in Nottingham last month. The facility adds OSD development and small-scale manufacturing capabilities to Codis’ offerings, enabling it to offer a single…

by Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list. Overpressure or vacuum conditions can compromise not only equipment, but also batch sterility, production timelines, and…

Ratio Therapeutics announced today that it closed a $70 million Series C financing to support its radiopharmaceutical development and manufacturing. Existing investors Duquesne Family Office and Bristol Myers Squibb participated. New investors Catalio Capital Management, Eli Lilly and Wasatch Group joined as well. Boston-based Ratio plans to use the proceeds to fund its next phase…